Show simple item record

Comparability of the tandem-R andIMx assays for the measurement of serum prostate-specific antigen

dc.contributor.authorJacobsen, Steven J.en_US
dc.contributor.authorLilja, Hansen_US
dc.contributor.authorKlee, George G.en_US
dc.contributor.authorWright, Jr, George L.en_US
dc.contributor.authorPettersson, Kimen_US
dc.contributor.authorOesterling, Joseph E.en_US
dc.date.accessioned2006-04-10T17:52:22Z
dc.date.available2006-04-10T17:52:22Z
dc.date.issued1994-10en_US
dc.identifier.citationJacobsen, Steven J., Lilja, Hans, Klee, George G., Wright, Jr, George L., Pettersson, Kim, Oesterling, Joseph E. (1994/10)."Comparability of the tandem-R andIMx assays for the measurement of serum prostate-specific antigen." Urology 44(4): 512-518. <http://hdl.handle.net/2027.42/31299>en_US
dc.identifier.urihttp://www.sciencedirect.com/science/article/B6VJW-4F5TTXG-36/2/dcacb2a80106db1b9a5e479013e0a0e2en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/31299
dc.identifier.urihttp://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=7524236&dopt=citationen_US
dc.description.abstractObjectives.To assess the comparability of the Tandem-R and IMx serumprostate-specific antigen (PSA) assays across levels of the ratio of free-to-total serum PSA found in a community-based population of healthy men.Methods.Banked serum samples from the baseline component of the Olmsted CountyStudy of Urinary Symptoms and Health Status Among Men were thawed and analyzed using the Tandem-R and IMx PSA assays. Serum levels also were determined for the free, noncomplexed form of PSA, PSA complexed to alpha-1 antichymotrypsin, and total PSA with a research-based immunofluorometric assay.Results.The results of the Tandem-R and IMx assays were strongly correlated at alllevels of the ratio of free-to-total serum PSA. The Spearman correlation coefficients ranged from 0.87 to 0.98 (all p Conclusions.For the majority of men, results of the Tandem-R and IMx PSA assays were virtually identical. The small differences found would not be of clinical significance for most men but should be considered when comparing results of different assays in sequential determinations for a specific man.en_US
dc.format.extent1123809 bytes
dc.format.extent3118 bytes
dc.format.mimetypeapplication/pdf
dc.format.mimetypetext/plain
dc.language.isoen_US
dc.publisherElsevieren_US
dc.titleComparability of the tandem-R andIMx assays for the measurement of serum prostate-specific antigenen_US
dc.typeArticleen_US
dc.rights.robotsIndexNoFollowen_US
dc.subject.hlbsecondlevelInternal Medicine and Specialtiesen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.contributor.affiliationumDepartment of Health Sciences Research, Section of Clinical Epidemiology and Department of Laboratory Medicine and Pathology, Division of Metabolic and Hematologic Biochemistry, Mayo Clinic and Mayo Foundation, Rochester, Minnesota, USA; Department of Clinical Chemistry, University of Lund, Mälmo, Sweden; Department of Microbiology and Immunology and Center for Urological Oncology,Eastern Virginia Medical School, Norfolk, Virginia, USA; Department of Biotechnology, University of Turku, Finland; The Michigan Prostate Institute, University of Michigan, Ann Arbor, Michigan, USA.en_US
dc.contributor.affiliationumDepartment of Health Sciences Research, Section of Clinical Epidemiology and Department of Laboratory Medicine and Pathology, Division of Metabolic and Hematologic Biochemistry, Mayo Clinic and Mayo Foundation, Rochester, Minnesota, USA; Department of Clinical Chemistry, University of Lund, Mälmo, Sweden; Department of Microbiology and Immunology and Center for Urological Oncology,Eastern Virginia Medical School, Norfolk, Virginia, USA; Department of Biotechnology, University of Turku, Finland; The Michigan Prostate Institute, University of Michigan, Ann Arbor, Michigan, USA.en_US
dc.contributor.affiliationumDepartment of Health Sciences Research, Section of Clinical Epidemiology and Department of Laboratory Medicine and Pathology, Division of Metabolic and Hematologic Biochemistry, Mayo Clinic and Mayo Foundation, Rochester, Minnesota, USA; Department of Clinical Chemistry, University of Lund, Mälmo, Sweden; Department of Microbiology and Immunology and Center for Urological Oncology,Eastern Virginia Medical School, Norfolk, Virginia, USA; Department of Biotechnology, University of Turku, Finland; The Michigan Prostate Institute, University of Michigan, Ann Arbor, Michigan, USA.en_US
dc.contributor.affiliationumDepartment of Health Sciences Research, Section of Clinical Epidemiology and Department of Laboratory Medicine and Pathology, Division of Metabolic and Hematologic Biochemistry, Mayo Clinic and Mayo Foundation, Rochester, Minnesota, USA; Department of Clinical Chemistry, University of Lund, Mälmo, Sweden; Department of Microbiology and Immunology and Center for Urological Oncology,Eastern Virginia Medical School, Norfolk, Virginia, USA; Department of Biotechnology, University of Turku, Finland; The Michigan Prostate Institute, University of Michigan, Ann Arbor, Michigan, USA.en_US
dc.contributor.affiliationumDepartment of Health Sciences Research, Section of Clinical Epidemiology and Department of Laboratory Medicine and Pathology, Division of Metabolic and Hematologic Biochemistry, Mayo Clinic and Mayo Foundation, Rochester, Minnesota, USA; Department of Clinical Chemistry, University of Lund, Mälmo, Sweden; Department of Microbiology and Immunology and Center for Urological Oncology,Eastern Virginia Medical School, Norfolk, Virginia, USA; Department of Biotechnology, University of Turku, Finland; The Michigan Prostate Institute, University of Michigan, Ann Arbor, Michigan, USA.en_US
dc.contributor.affiliationumDepartment of Health Sciences Research, Section of Clinical Epidemiology and Department of Laboratory Medicine and Pathology, Division of Metabolic and Hematologic Biochemistry, Mayo Clinic and Mayo Foundation, Rochester, Minnesota, USA; Department of Clinical Chemistry, University of Lund, Mälmo, Sweden; Department of Microbiology and Immunology and Center for Urological Oncology,Eastern Virginia Medical School, Norfolk, Virginia, USA; Department of Biotechnology, University of Turku, Finland; The Michigan Prostate Institute, University of Michigan, Ann Arbor, Michigan, USA.en_US
dc.identifier.pmid7524236en_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/31299/1/0000205.pdfen_US
dc.identifier.doihttp://dx.doi.org/10.1016/S0090-4295(94)80049-9en_US
dc.identifier.sourceUrologyen_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.